Cardiovascular effects of glukagon-like peptide-1 and its agonist: more than just cardiovascularly safe antidiabetics?
2012
Abstract
Cardiovascular complications are a major cause of morbidity and mortality in patients suffering type 2 diabetes and the most important goal of the complex treatment of these patiens is reducing their overall levels of cardiovascular risk. Experimental and smallscale clinical studies have shown that the recently introduced incretin-based therapy has a very good potential for cardio-protective effects.